# idiopathic pulmonary fibrosis (IPF) - gpt-5.6-luna

- Benchmark system: E2seq + Agent RAG
- Repeat: 5
- Task type: PROGNOSIS
- Tissue / sample source: lung tissue
- Comparison or endpoint: all-cause mortality
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: OpenAI / gpt-5.6-luna
- Message SHA-256: d9fe74e971569d03f1ace047ce334e08d788b93d2057913b4d42b34da6d57d2f
- Response HTTP status: 200
- Prompt tokens: 46291
- Completion tokens: 17673
- Reasoning tokens: 0
- Total tokens: 63964
- API requests reported: 3
- Elapsed seconds: 149.492
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1387.824
- Question handoff seconds: 1401.194
- Final benchmark system: E2seq; file rank 5/5; original repeat 5; model vendor: OpenAI

---
## Data-quality warning and interpretation scope

The statistical output is technically suspicious and should not be interpreted as a stable quantitative prognostic model without re-analysis. The ledger reports **100 unique genes**, **93 risk-associated and 7 protective-associated**, with **all 100 having P≤0.05 and FDR≤0.05**. Several rows have extreme HRs near \(10^{-22}\) or \(10^{21}\), reported P values of exactly 0, and control-probe, uncharacterized, olfactory-receptor, or poorly annotated features. There are also **29 duplicated genes/probes**, including a direction conflict for **XLOC_003303**. These patterns are compatible with complete or quasi-complete separation, probe/annotation artifacts, coding or transformation problems, or an overfitted survival model.

Accordingly, the HRs and FDRs are the direct evidence for this cohort, but their absolute magnitudes and nominal significance should be treated as unreliable until the survival analysis is reconstructed. The following is therefore a **clearly labelled exploratory biological interpretation** of the more biologically interpretable signals. **External statistical validation was not performed**: no independent-cohort HR, P value, FDR, or validation model was supplied.

## 1. Overall biological interpretation

The interpretable portion of the signature is dominated by **higher mortality associated with coordinated inflammatory, epithelial-injury, extracellular-matrix/remodelling, growth-factor, and metabolic/redox programs**. Representative risk-associated genes include:

- **Inflammation and myeloid recruitment:** S100A12, CXCL1, CCL7, CXCR1, CD177, MMP25, SPP1, SELL, and STAB1.
- **Abnormal or injured epithelial state:** MUC1, SLC34A2, CEACAM6, CEACAM7, SFTPB, SFTA2, AGR3, KRT17, KRT23, SPRR1A, and MAL2.
- **Matrix remodelling and cell motility:** HTRA1, EFEMP1, CHST15, TM4SF1, FBLIM1, ENAH, MARCKS, MTSS1, and F5.
- **Growth-factor signalling:** HGF, MET, NRG1, SPRY2, and MUC1.
- **Redox and metabolic adaptation:** SLC7A11, SOD3, CYP4F3, ACOX2, ALDH1A3, STEAP4, SLC39A8, and SLC6A8.

This pattern is biologically compatible with a high-severity IPF lung environment characterized by inflammatory-cell recruitment, epithelial stress or aberrant epithelial activation, matrix remodelling, and altered tissue repair. However, because the samples are bulk lung tissue, the signature may reflect **differences in cell composition or disease severity rather than gene regulation within a single cell type**.

The seven protective-associated features should not currently be interpreted as a coherent protective biological program. Several extreme protective/risk values involve controls or poorly characterized features, while **LOC100128226** has HR \(=0.0070320732\), P \(=1.2409004\times10^{-38}\), and FDR \(=4.7992385\times10^{-35}\). That result is statistically striking in the supplied table but requires probe identity, expression distribution, and independent validation before biological interpretation.

## 2. Core biological programs

### Program 1 — Neutrophil and chemokine-mediated inflammatory recruitment

- **Association:** Risk-associated with mortality.
- **Supporting genes:** S100A12, CXCL1, CCL7, CXCR1, CD177, MMP25, SELL, SPP1, and STAB1.
- **Relevant annotations:** GO **Neutrophil Migration** (GO:1990266); KEGG **Chemokine signaling pathway**; Reactome **Neutrophil degranulation** and NF-κB-related inflammatory signalling.
- **Interpretation:** Multiple genes represent neutrophil recruitment, activation, adhesion, degranulation, or inflammatory communication rather than a single isolated marker. S100A12 has QuickGO annotations for inflammatory response and monocyte chemotaxis and Reactome annotations for neutrophil degranulation and AGE-receptor/NF-κB signalling. STRING records connect S100A12 with AGER, TLR4, S100A8, and S100A9; these are interaction-context records, not interactions calculated from this cohort.
- **Evidence strength:** **Supported hypothesis.** Direct cohort evidence is broad and directionally consistent across many risk-associated genes; pathway and network annotations provide biological plausibility.
- **Limitations:** The supplied pathway results are retrieved annotations and recurrence summaries, not a newly calculated enrichment P value. This program could reflect increased neutrophil abundance in severe lung tissue rather than a causal neutrophil transcriptional mechanism. SPP1 and STAB1 may also reflect macrophage or monocyte populations.

### Program 2 — Injured or aberrantly activated alveolar/airway epithelial state

- **Association:** Risk-associated with mortality.
- **Supporting genes:** MUC1, SLC34A2, CEACAM6, CEACAM7, SFTPB, SFTA2, AGR3, KRT17, KRT23, SPRR1A, MUC21, MAL2, PRSS8, and SFTA2.
- **Relevant annotations:** Epithelial structural and membrane programs; the supplied annotation batch includes epithelial-cell signalling and plasma-membrane/extracellular-region categories.
- **Interpretation:** The simultaneous risk association of surfactant-associated genes, epithelial membrane/adhesion genes, mucins, keratins, and secretory genes suggests altered epithelial composition or a disease-associated epithelial state. The combination is more informative than any one gene: it may represent epithelial injury, metaplastic repair, secretory-cell expansion, or loss of normal alveolar identity.
- **Evidence strength:** **Supported hypothesis**, particularly for an epithelial-state association.
- **Limitations:** Bulk lung expression cannot distinguish epithelial activation from increased epithelial representation, airway contamination, or sampling differences. The displayed literature includes SFTA2 in a lung-cancer genetic/pathway study (PMID: **37471639**), but that is not evidence of prognostic relevance in IPF. Similarly, KRT23 literature in metabolic liver disease (PMID: **40487984**) should not be extrapolated directly to IPF.

### Program 3 — Extracellular-matrix remodelling, adhesion, and tissue motility

- **Association:** Risk-associated with mortality.
- **Supporting genes:** HTRA1, EFEMP1, CHST15, TM4SF1, FBLIM1, ENAH, MARCKS, MTSS1, F5, PRSS23, and SUSD2.
- **Relevant annotations:** Extracellular-region, plasma-membrane, cell-adhesion, cytoskeletal, and lamellipodium-related annotations; the retrieved GO batch included **Negative Regulation of Lamellipodium Organization** (GO:1902744).
- **Interpretation:** HTRA1 and EFEMP1 are compatible with extracellular proteostasis and matrix remodelling, while CHST15 may reflect altered matrix glycosaminoglycan modification. TM4SF1, FBLIM1, ENAH, MARCKS, and MTSS1 provide a complementary cell-adhesion and motility component. Collectively, this is consistent with activated fibroblast–epithelial–vascular interfaces and abnormal tissue remodelling.
- **Evidence strength:** **Supported hypothesis**, based on multi-gene convergence and extracellular/cell-motility annotations.
- **Limitations:** The current results do not establish increased collagen production, fibroblast-specific activation, or causality. Matrix-associated signals may be strongly driven by tissue architecture and the relative abundance of fibroblasts, endothelial cells, and epithelial cells.

### Program 4 — HGF/MET and EGFR-family growth-factor signalling

- **Association:** Risk-associated with mortality.
- **Supporting genes:** HGF, MET, NRG1, SPRY2, MUC1, EFEMP1, and possibly TM4SF1.
- **Relevant annotations:** STRING network context identifies an **EGFR-associated group** containing EFEMP1, HGF, MET, MUC1, and NRG1; MET and SPRY2 are linked through a CBL-associated network record.
- **Interpretation:** HGF–MET and NRG1–EGFR-family signalling are plausible components of epithelial repair, migration, survival, and remodelling. Their joint risk association suggests that growth-factor signalling may mark an activated repair state associated with worse outcome. This is not evidence that these pathways are oncogenic in IPF or that blocking them would be beneficial.
- **Evidence strength:** **Supported hypothesis**, with pathway/network plausibility and multiple risk-associated genes.
- **Limitations:** The supplied STRING records do not establish that all genes physically interact in IPF lung. Some relationships are likely pathway co-membership or indirect signalling. HGF and MET can support repair in some contexts, so the direction of therapeutic intervention is uncertain.

### Program 5 — Oxidative-stress, lipid, and nutrient-transport adaptation

- **Association:** Risk-associated with mortality.
- **Supporting genes:** SLC7A11, SOD3, CYP4F3, ACOX2, ALDH1A3, STEAP4, SLC39A8, SLC6A8, and ANKRD22.
- **Relevant annotations:** Metabolic, redox, transport, and xenobiotic-related annotations; S100A12 annotations also include a xenobiotic metabolic process.
- **Interpretation:** SLC7A11 suggests increased capacity for cystine import and glutathione-related redox buffering, while SOD3 represents extracellular antioxidant defence. CYP4F3, ACOX2, ALDH1A3, STEAP4, and metal/nutrient transport genes indicate altered lipid, aldehyde, and redox metabolism. This may reflect adaptation to oxidative and metabolic stress in damaged lung tissue.
- **Evidence strength:** **Exploratory to supported hypothesis.** The program contains multiple risk-associated genes but is less specific to IPF than the inflammatory and epithelial programs.
- **Limitations:** These genes have substantial cell-type and context dependence. No metabolomic measurement or pathway activity score was supplied, and the retrieved metabolic records are contextual rather than independent statistical validation.

## 3. Key genes and interaction modules

The following candidates are prioritized for biological follow-up, not because external records outrank the uploaded statistics, but because they connect the strongest interpretable programs.

| Candidate | Current dataset | Program and proposed relationship | Evidence type and interpretation |
|---|---:|---|---|
| **S100A12** | HR **2.5346746**, P **2.5789837e-09**, FDR **5.4858851e-06**; risk-associated | Inflammatory recruitment and neutrophil activation. Relationships with S100A8/A9, AGER, and TLR4 are reported in STRING; these are database-supported protein/signalling relationships, not cohort-derived physical interaction measurements. | Direct survival association plus QuickGO/Reactome support. Strong candidate for validation, but likely sensitive to myeloid composition. |
| **CXCL1–CXCR1 inflammatory module** | CXCL1 HR **2.9896541**, FDR **3.7334111e-05**; CXCR1 HR **3.2808305**, FDR **1.6046748e-05** | Chemokine–receptor pathway co-membership and plausible ligand–receptor signalling. CXCL1 and CXCR1 are not thereby proven to interact physically in the lung samples. | Direct risk associations plus chemokine-pathway annotation; cell-type attribution remains uncertain. |
| **SPP1–STAB1 macrophage/remodelling module** | SPP1 HR **3.3988408**, FDR **3.991039e-05**; STAB1 HR **3.2915921**, FDR **3.1456778e-05** | Likely macrophage-associated inflammatory/remodelling state. Their relationship is best described as co-expression or cell-state/pathway association unless a specific physical interaction is demonstrated. | Direct risk associations and immune/tissue annotations; may primarily indicate macrophage abundance. |
| **HGF–MET axis** | HGF HR **2.926959**, FDR **1.0892619e-05**; MET HR **2.5264463**, FDR **1.4677765e-05** | HGF is a ligand for MET in canonical signalling. This is a regulatory/signalling relationship, not evidence of direct protein binding measured in this dataset. | Direct risk associations plus pathway/network records. Causal direction and therapeutic value are unresolved. |
| **NRG1–EGFR-family signalling group** | NRG1 HR **2.7571185**, FDR **6.852395e-06**; MUC1 HR **2.324446**, FDR **1.0892619e-05** | NRG1 can signal through ERBB-family receptors; MUC1 may act as a membrane-associated signalling modulator. This is indirect pathway co-membership unless receptor-specific evidence is supplied. | Direct risk associations and EGFR-associated STRING context; no IPF-specific functional confirmation supplied. |
| **HTRA1–EFEMP1 matrix module** | HTRA1 HR **4.3017004**, FDR **2.5707761e-06**; EFEMP1 HR **2.3286851**, FDR **2.7318548e-05** | Extracellular matrix/proteostasis co-membership and a putative remodelling relationship. Not a demonstrated direct physical interaction. | Strong direct association of two interpretable matrix-related genes; bulk-tissue confounding is important. |
| **TM4SF1–motility/vascular interface** | TM4SF1 HR **2.5703046**, FDR **1.3259078e-05** | Membrane-associated migration and vascular/epithelial remodelling; likely pathway or co-expression relationship with ENAH, FBLIM1, and MARCKS. | Direct risk association and membrane/motility annotations; cell lineage must be resolved. |
| **SLC7A11–SOD3 redox module** | SLC7A11 HR **3.5163423**, FDR **1.0940918e-05**; SOD3 HR **2.3705165**, FDR **2.7318548e-05** | Complementary intracellular and extracellular redox-response components. Relationship is functional/pathway co-membership, not direct physical interaction. | Direct risk associations and biologic plausibility; no redox measurements were supplied. |
| **MERTK–STAB1 phagocyte/remodelling state** | MERTK HR **3.7021145**, FDR **1.0499641e-05**; STAB1 HR **3.2915921**, FDR **3.1456778e-05** | Putative macrophage/efferocytosis and tissue-remodelling program. Likely cell-state co-expression or indirect relationship. | Direct risk associations plus immune/tissue annotation; strongly vulnerable to macrophage abundance. |
| **SFTA2/SFTPB epithelial-sur factant module** | SFTA2 HR **2.2481876**, FDR **2.9216189e-05**; SFTPB HR **2.6648273**, FDR **3.3741902e-05** | Surfactant/epithelial-state co-expression and epithelial injury or altered cellular composition. Not a direct interaction claim. | Direct risk associations and lung epithelial context; interpretation is not specific for disease mechanism. |

## 4. Validation priorities

### 1. Confounding or composition check — resolve lung-cell composition

- **Why prioritize:** The inflammatory and epithelial signals could arise from different proportions of neutrophils, macrophages, epithelial cells, fibroblasts, or endothelial cells.
- **Current evidence:** Coordinated risk associations for S100A12, CXCL1, CD177, SPP1, STAB1, MUC1, SLC34A2, SFTPB, and keratins.
- **External evidence:** GO, Reactome, tissue-expression, and network records support the expected cell-type biology, but these are not independent survival validation.
- **Next step:** Apply validated bulk deconvolution, inspect marker scores, and, ideally, use single-cell or spatial transcriptomics with matched clinical covariates. Refit survival models after cell-composition adjustment.
- **Conclusion status:** **Established evidence** that composition is a major plausible alternative explanation; the specific causal interpretation is not established.

### 2. Biomarker — test a compact multi-program prognostic score

- **Why prioritize:** The current result contains many correlated genes and is unsuitable as a clinical signature without shrinkage and validation.
- **Current evidence:** Broad risk association across inflammatory, epithelial, matrix, and metabolic genes, but with suspiciously universal significance.
- **External evidence:** Tissue and disease annotations support plausibility; **external statistical validation was not performed**.
- **Next step:** Reprocess probes and duplicates, use penalized Cox or pre-specified gene scores, perform internal bootstrap optimism correction, and test in an independent IPF cohort with discrimination, calibration, and incremental value over age, sex, lung function, disease stage, and treatment.
- **Conclusion status:** **Exploratory hypothesis**.

### 3. Mechanistic hypothesis — myeloid S100A12/chemokine signalling contributes to severe disease

- **Why prioritize:** S100A12, CXCL1, CXCR1, CD177, CCL7, and SPP1 form the most coherent inflammatory signal.
- **Current evidence:** All are risk-associated in the supplied table; S100A12 has annotations for chemotaxis, neutrophil degranulation, AGER/TLR4 signalling, and NF-κB-related pathways.
- **External evidence:** QuickGO, Reactome, and STRING support inflammatory relationships; these records may overlap with common literature and are not IPF-cohort replication.
- **Next step:** Measure protein levels and spatial localization, then test S100A12 or chemokine perturbation in primary IPF lung cells or organoid–immune co-cultures, with neutrophil recruitment and epithelial injury as endpoints.
- **Conclusion status:** **Supported hypothesis**, not a causal conclusion.

### 4. Interaction/network hypothesis — HGF–MET and NRG1–EGFR-family signalling

- **Why prioritize:** HGF, MET, NRG1, MUC1, EFEMP1, and SPRY2 connect risk-associated epithelial, matrix, and signalling programs.
- **Current evidence:** HGF, MET, NRG1, MUC1, and SPRY2 are all risk-associated; retrieved STRING context places several in EGFR- or MET-related networks.
- **External evidence:** Network and pathway records support signalling plausibility, but they do not demonstrate pathway activation in these samples.
- **Next step:** Use phosphoproteomics or phospho-immunoblotting for MET/ERBB/ERK signalling, ligand–receptor assays, and perturbation experiments in relevant epithelial or fibroblast models.
- **Conclusion status:** **Exploratory hypothesis**.

### 5. Therapeutic target — inflammatory S100A12/AGER or downstream chemokine axis

- **Why prioritize:** This axis is mechanistically coherent and potentially measurable, making it more tractable than many poorly annotated candidates.
- **Current evidence:** S100A12 HR **2.5346746** with FDR **5.4858851e-06**, together with risk-associated CXCL1, CXCR1, CCL7, CD177, and SPP1.
- **External evidence:** S100A12–AGER/TLR4 and NF-κB associations are supported by STRING and Reactome. No supplied clinical trial or independent IPF efficacy statistic establishes benefit from targeting this axis.
- **Next step:** Confirm target expression in the relevant lung cell populations, test pathway blockade in ex vivo IPF tissue or animal models, and assess infection and host-defence consequences.
- **Conclusion status:** **Exploratory therapeutic hypothesis**. Drug availability or pathway plausibility alone does not establish efficacy or safety in IPF.

## 5. Evidence grounding and conflicts

- **Direct input evidence:** The survival table is the only cohort-level statistical evidence. Most interpretable genes have HRs above 1 with FDR values approximately \(10^{-5}\) to \(10^{-7}\), whereas several control or poorly annotated features have extreme HRs and P=0.
- **Pathway and ontology evidence:** The supplied batch identified neutrophil migration, antimicrobial humoral response, chemokine signalling, epithelial signalling, and lamellipodium-related terms. These are contextual annotations; no new enrichment calculation or enrichment significance was performed during synthesis.
- **Network evidence:** The supplied STRING summary reports 50 edges and highlights EGFR-, CD44-, CXCL5/CXCL6-, FN1-, and CBL-related network contexts. These relationships may represent direct physical interactions, predicted associations, co-expression, or pathway links depending on the individual record; they should not be treated as cohort-derived networks.
- **Tissue and disease evidence:** GTEx, HPA, GWAS, Reactome, and disease databases provide plausibility and annotation, but record presence or source coverage is not replication.
- **Literature evidence:** The question-specific search retrieved 658 PubMed and 860 Europe PMC records overall, but the displayed examples are largely from other diseases, including lung cancer, liver disease, and neuropsychiatric disease. For example, FAM198B in lung adenocarcinoma (PMID: **29217529**) and SFTA2 in lung-cancer risk analysis (PMID: **37471639**) should not be treated as evidence for IPF mortality. The literature search therefore supports biological context only and does not provide independent IPF prognostic validation.
- **Conflicts:** The strongest conflict is internal to the statistical output: biologically implausible features, extreme HRs, P=0 values, duplicates, and a direction conflict coexist with a highly coherent risk-associated bulk-tissue pattern. This suggests that the program-level biology may be informative while the numerical model output remains technically unreliable.

## 6. Major limitations and alternative explanations

1. **Model separation, coding, or numerical underflow:** HRs near \(10^{-22}\) and \(10^{21}\), P=0, and universal FDR significance suggest unstable estimation. Reconstruct the survival model, inspect event counts and censoring, verify expression scaling, and use penalized or Firth Cox regression.

2. **Duplicate probes and annotation problems:** Twenty-nine duplicated genes/probes and several controls, lncRNAs, loci, and poorly characterized features can inflate apparent evidence. Re-map probes to the current genome, collapse probes using a pre-specified rule, remove controls, and examine per-probe expression distributions.

3. **Cellular composition and tissue architecture:** Neutrophil, macrophage, epithelial, endothelial, and fibroblast abundance may drive the signature. Use deconvolution, histology, spatial methods, or single-cell data, followed by adjusted survival analysis.

4. **Clinical confounding:** Mortality-associated expression may track age, sex, baseline lung function, disease stage, acute exacerbation, treatment exposure, smoking, infection, or sampling site. Multivariable and stratified analyses with time-dependent or competing clinical factors are needed.

5. **Association does not establish mechanism:** A high HR identifies association with all-cause mortality, not a causal driver, drug target, or IPF-specific death mechanism. Replication in an independent IPF cohort and functional perturbation are required.

Overall, the most defensible exploratory model is that higher mortality is associated with a bulk-lung state combining inflammatory-cell recruitment, epithelial injury or remodelling, matrix/motility activity, growth-factor signalling, and oxidative-metabolic adaptation; the biological program is plausible, but the extreme and uniformly significant statistics require technical correction and independent validation before clinical or mechanistic claims are made.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=0, external claims checked=0, external mismatches=0, status=passed.

Answer model API: OpenAI / gpt-5.6-luna

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 77/100 selected items (partially returned; some queries failed); cbioportal 78/100 selected items (records returned); chembl 13/100 selected items (partially returned; some queries failed); civic 8/100 selected items (records returned); clinicaltrials 48/100 selected items (records returned); clinvar 78/100 selected items (records returned); ensembl 25/100 selected items (partially returned; some queries failed); europepmc 860 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 83/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 78/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 81/100 selected items (partially returned; some queries failed); mygene 91/100 selected items (records returned); omnipath 47/100 selected items (records returned); opentargets 80/100 selected items (partially returned; some queries failed); pubmed 658 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 83/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 84/100 selected items (records returned)
Local databases: gutmgene 3/100 selected items (records returned); hmdb 32/100 selected items (records returned); string 79/100 selected items (records returned); trrust 25/100 selected items (records returned)
